NCT02274740View on ClinicalTrials.gov

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Type II Diabetes Mellitus
Interventions
DRUG

LIXISENATIDE AVE0010

Pharmaceutical form:solution Route of administration: subcutaneous

DRUG

metformin

Pharmaceutical form:tablet Route of administration: oral

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY